Skip to main content
OpenTrials

Clinical trial condition

Fallopian Tube Neoplasms

Explore clinical trials studying Fallopian Tube Neoplasms. Study availability and eligibility vary by location and protocol.

600 public trials 90 recruiting studies
Refine in advanced search Browse all conditions

Fallopian Tube Neoplasms trial results

Completed

A Trial Evaluating TG4050 in Ovarian Carcinoma.

NCT03839524

Conditions
Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +17 more
Locations
  • Mayo Clinic Phoenix Phoenix, Arizona, United States
  • Mayo Clinic Jacksonville Jacksonville, Florida, United States
  • Mayo Clinic Rochester Rochester, Minnesota, United States
  • Institut Curie Paris, France
View Trial Details
Completed

Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT03776812

Conditions
Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +17 more
Locations
  • Site Reference ID/Investigator #004 Birmingham, Alabama, United States
  • Site Reference ID/Investigator #038 Scottsdale, Arizona, United States
  • Site Reference ID/Investigator #032 Denver, Colorado, United States
  • Site Reference ID/Investigator #001 Chicago, Illinois, United States
View all 24 locations
View Trial Details
Completed

Nivolumab With or Without Ipilimumab in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

NCT02498600

Conditions
Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +17 more
Locations
  • Sutter Auburn Faith Hospital Auburn, California, United States
  • Sutter Cancer Centers Radiation Oncology Services-Auburn Auburn, California, United States
  • Alta Bates Summit Medical Center-Herrick Campus Berkeley, California, United States
  • Sutter Cancer Centers Radiation Oncology Services-Cameron Park Cameron Park, California, United States
View all 201 locations
View Trial Details
Completed

Outcomes After Secondary Cytoreductive Surgery With or Without Carboplatin Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Followed by Systemic Combination Chemotherapy for Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT01767675

Conditions
Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +17 more
Locations
  • Hartford Healthcare Cancer Institute @ Hartford Hospital Hartford, Connecticut, United States
  • Baptist Health South Florida Miami, Florida, United States
  • University of Chicago Medical Center Chicago, Illinois, United States
  • Mayo Clinic Rochester, Minnesota, United States
View Trial Details
Completed

Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate in Ovarian & Endometrial Cancers

NCT03748186

Conditions
Adenocarcinoma, Adnexal Diseases, Carcinoma, +29 more
Locations
  • Arizona Oncology - Tucson Tucson, Arizona, United States
  • UCLA Jonsson Comprehensive Cancer Center Clinical Research Unit Los Angeles, California, United States
  • Sutter Health- Palo Alto Medical Foundation San Francisco, California, United States
  • Rocky Mountain Cancer Center Aurora, Colorado, United States
View all 27 locations
View Trial Details

Related conditions